<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005149.pub3" GROUP_ID="ARI" ID="009704033111141361" MERGED_FROM="" MODIFIED="2013-12-02 05:35:58 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A098" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-12-02 05:35:58 +0000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2009-07-14 10:47:03 +1000" MODIFIED_BY="[Empty name]">Intranasal steroids for acute sinusitis</TITLE>
<CONTACT MODIFIED="2013-12-02 05:35:58 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="17887" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anca</FIRST_NAME><LAST_NAME>Zalmanovici Trestioreanu</LAST_NAME><POSITION>Attending Family Physician</POSITION><EMAIL_1>anca_z@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>Beilinson Campus, Rabin Medical Center</ORGANISATION><ADDRESS_1>39 Jabotinski Street</ADDRESS_1><CITY>Petah Tikva</CITY><ZIP>49100</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 3 937 7340</PHONE_1><FAX_1>+972 3 922 2045</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-02 05:35:58 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="17887" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anca</FIRST_NAME><LAST_NAME>Zalmanovici Trestioreanu</LAST_NAME><POSITION>Attending Family Physician</POSITION><EMAIL_1>anca_z@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>Beilinson Campus, Rabin Medical Center</ORGANISATION><ADDRESS_1>39 Jabotinski Street</ADDRESS_1><CITY>Petah Tikva</CITY><ZIP>49100</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 3 937 7340</PHONE_1><FAX_1>+972 3 922 2045</FAX_1></ADDRESS></PERSON><PERSON ID="17886" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Yaphe</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Director of Research</POSITION><EMAIL_1>yonahyaphe@hotmail.com</EMAIL_1><EMAIL_2>yonahyaphe@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>School of Health Science</DEPARTMENT><ORGANISATION>University of Minho</ORGANISATION><CITY>Braga</CITY><COUNTRY CODE="PT">Portugal</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-08-20 10:06:23 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="5" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="5" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-20 10:07:46 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-20 10:07:46 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-20 10:07:33 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated. No new trials were identified in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-08-20 10:06:53 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-20 10:06:53 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Searches updated. No new studies found for inclusion or exclusion. The conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-09 11:03:19 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="3" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-06-14 21:35:03 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Two trials identified in the updated search and three trials for which data are not available were added to the excluded studies list (<LINK REF="STD-Bachert-2007" TYPE="STUDY">Bachert 2007</LINK>; <LINK REF="STD-Jurkiewicz-2004" TYPE="STUDY">Jurkiewicz 2004</LINK>; <LINK REF="STD-Meltzer-2000" TYPE="STUDY">Meltzer 2000</LINK>; <LINK REF="STD-Tutkun-1996" TYPE="STUDY">Tutkun 1996</LINK>; <LINK REF="STD-Williamson-2007" TYPE="STUDY">Williamson 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-06-04 09:58:07 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="28" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-20 13:13:26 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-05-07 13:57:49 +1000" MODIFIED_BY="[Empty name]">Steroids for acute sinusitis in adults and children</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-20 13:13:26 +1000" MODIFIED_BY="[Empty name]">
<P>Acute sinusitis is a common reason for primary care visits; it is one of the 10 most common diagnoses in outpatient clinics, presenting with various symptoms and signs that include purulent nasal discharge and congestion and cough lasting beyond the typical seven to 10 days of a viral upper respiratory infection. There have been suggestions, based on studies of allergic rhinitis and chronic sinusitis, that intranasal corticosteroids (INCS) may relieve symptoms and hasten recovery in acute sinusitis due to their anti-inflammatory properties.</P>
<P>A critical systematic review of the literature found four well-conducted, randomised, placebo-controlled intervention studies, involving 1943 participants treated for 15 or 21 days. The results suggest that there may be a modest effect with INCS in the resolution or improvement of symptoms. Only minor adverse events such as epistaxis, headache and nasal itching were reported. Given the small number of studies included in this review, it is recommended that further randomised controlled trials be conducted. The evidence is up to date as of May 2013.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Acute sinusitis is a common reason for primary care visits. It causes significant symptoms and often results in time off work and school.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-05-07 13:55:43 +1000" MODIFIED_BY="[Empty name]">
<P>We examined whether intranasal corticosteroids (INCS) are effective in relieving symptoms of acute sinusitis in adults and children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL 2013, Issue 4, MEDLINE (January 1966 to May week 2, 2013), EMBASE (1990 to May 2013) and bibliographies of included studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-06-14 21:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing INCS treatment to placebo or no intervention in adults and children with acute sinusitis. Acute sinusitis was defined by clinical diagnosis and confirmed by radiological evidence or by nasal endoscopy. The primary outcome was the proportion of participants with either resolution or improvement of symptoms. Secondary outcomes were any adverse events that required discontinuation of treatment, drop-outs before the end of the study, rates of relapse, complications and return to school or work.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-04-20 07:22:07 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data, assessed trial quality and resolved discrepancies by consensus.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>No new trials were found for inclusion in this update. Four studies involving 1943 participants with acute sinusitis met our inclusion criteria. The trials were well-designed and double-blind and studied INCS versus placebo or no intervention for 15 or 21 days. The rates of loss to follow-up were 7%, 11%, 41% and 10%. When we combined the results from the three trials included in the meta-analysis, participants receiving INCS were more likely to experience resolution or improvement in symptoms than those receiving placebo (73% versus 66.4%; risk ratio (RR) 1.11; 95% confidence interval (CI) 1.04 to 1.18). Higher doses of INCS had a stronger effect on improvement of symptoms or complete relief: for mometasone furoate 400 µg versus 200 µg (RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% CI 0.98 to 1.11). No significant adverse events were reported and there was no significant difference in the drop-out and recurrence rates for the two treatment groups and for groups receiving higher doses of INCS.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-08-20 10:30:20 +1000" MODIFIED_BY="[Empty name]">
<P>Current evidence is limited for acute sinusitis confirmed by radiology or nasal endoscopy but supports the use of INCS as a monotherapy or as an adjuvant therapy to antibiotics. Clinicians should weigh the modest but clinically important benefits against possible minor adverse events when prescribing therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-06-14 21:39:58 +1000" MODIFIED_BY="[Empty name]">
<P>Acute sinusitis is a common reason for primary care visits. It causes significant symptoms and often results in time off work and school. It is one of the 10 most common diagnoses in ambulatory practice and is the fifth most common diagnosis for which an antibiotic is prescribed. Primary care physicians tend to think of sinusitis as an acute bacterial infection and consequently prescribe antibiotics in 85% to 98% of cases. However, sinusitis is frequently caused by a viral infection. According to epidemiological estimates, only 0.2% to 2% of viral upper respiratory tract infections in adults are complicated by bacterial rhinosinusitis. It will often resolve in most patients without antibiotic treatment, even if it is bacterial in origin. Since no simple and accurate practice-based test exists for acute bacterial sinusitis, clinicians rely on clinical findings to make the diagnosis. Signs and symptoms of acute bacterial sinusitis and those of prolonged viral upper respiratory tract infection are very similar, resulting in frequent misclassification of viral cases (<LINK REF="REF-Snow-2001" TYPE="REFERENCE">Snow 2001</LINK>).</P>
<P>The common cold is associated with frequent and variable anatomical involvement of the upper airways, including occlusion and abnormalities in the sinus cavities (<LINK REF="REF-Gwaltney-1994" TYPE="REFERENCE">Gwaltney 1994</LINK>). Rhinorrhoea, sinus tenderness, purulent secretions and a history of sinusitis were significant predictors for the diagnosis of sinusitis in a retrospective analysis (<LINK REF="REF-Little-2000" TYPE="REFERENCE">Little 2000</LINK>). Acute sinusitis is defined as an inflammation of the sinuses with the symptom complex lasting less than eight weeks in adults and less than 12 weeks in children (<LINK REF="REF-Kaliner-1997" TYPE="REFERENCE">Kaliner 1997</LINK>).</P>
<P>Clinical diagnosis is made through the appearance of a characteristic constellation of symptoms and signs, including purulent nasal discharge and congestion and cough lasting beyond the typical seven to 10 days for a viral upper respiratory infection. Fever and facial pain may also occur. Diagnosis is often confirmed by sinus imaging; in this area, the use of computerised tomography (CT) scanning is gaining favour (<LINK REF="REF-Gwaltney-1995" TYPE="REFERENCE">Gwaltney 1995</LINK>).</P>
<P>Inflammation of nasal mucosa plays an essential role in the development of sinusitis (<LINK REF="STD-Tutkun-1996" TYPE="STUDY">Tutkun 1996</LINK>). Sinusitis is invariably accompanied by inflammation of the contiguous nasal mucosa, therefore rhinosinusitis has become the preferred term (<LINK REF="REF-Snow-2001" TYPE="REFERENCE">Snow 2001</LINK>). The precipitating factor in acute sinusitis appears to be blockage of the sinus ostium. The obstruction, as well as mucus retention and infection, produce the characteristic signs and symptoms of rhinosinusitis. Although many conditions may lead to ostial closure, viral upper respiratory infections and allergic inflammation are by far the most frequent and important (<LINK REF="REF-Shapiro-1992" TYPE="REFERENCE">Shapiro 1992</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-09-03 11:08:25 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment of sinusitis is aimed at eliminating causative factors and controlling the inflammatory and infectious components (<LINK REF="REF-Becker-2003" TYPE="REFERENCE">Becker 2003</LINK>). It has been theorised that by decreasing the inflammatory response and reducing the mucosal swelling, a topical intranasal steroid would promote drainage and increase aeration of the sinuses, thus hastening the elimination of infectious organisms and decreasing the frequency and severity of recurrences (<LINK REF="REF-Mygind-1976" TYPE="REFERENCE">Mygind 1976</LINK>). There is evidence that asthma, otitis media with effusion and acute sinusitis may all benefit from such therapy as well (<LINK REF="REF-Scadding-2000" TYPE="REFERENCE">Scadding 2000</LINK>). A recent Cochrane review found that systemic corticosteroids as adjunctive to antibiotic treatment were effective for the short-term relief of symptoms in acute sinusitis; the authors mention that the data for this review are limited and there is a significant risk of bias (<LINK REF="REF-Venekamp-2011" TYPE="REFERENCE">Venekamp 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>In addition to treating seasonal and perennial rhinitis (possible predisposing factors to the development of acute rhinosinusitis), intranasal corticosteroids (INCS) might be beneficial in reducing inflammation in the treatment of sinusitis and may help decrease secondary rhinovirus infections (<LINK REF="REF-Gawchik-2000" TYPE="REFERENCE">Gawchik 2000</LINK>). The mode of action of INCS is complex. It is not known whether INCS penetrate the nasal mucosa or act on target cells. However, their low systemic activity supports the concept of local action on nasal mucosa. This local effect can influence a variety of inflammatory cells and their mediators such as epithelial cells, lymphocytes, basophiles, mast cells and Langerhans cells. Corticosteroid-induced inhibition of the immunoglobulin E dependent release of histamine is a possible but unproven mode of action (<LINK REF="REF-Mygind-2001" TYPE="REFERENCE">Mygind 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>The management of rhinosinusitis depends on a number of variables related to the duration and severity of symptoms in the individual patient. Since there are a variety of conservative and pharmacological interventions available, the physician can find it difficult to develop a cohesive and logical approach to treatment (<LINK REF="REF-Benninger-1997" TYPE="REFERENCE">Benninger 1997</LINK>). A small benefit for clinical outcomes was observed in patients treated with antibiotics for uncomplicated acute sinusitis; 80% of participants treated without antibiotics improved within two weeks (<LINK REF="REF-Ahovuo_x002d_Saloranta-2011" TYPE="REFERENCE">Ahovuo-Saloranta 2011</LINK>). No clear evidence of efficacy of decongestants, antihistamines and nasal irrigations for acute sinusitis in children was found in a recent Cochrane Review (<LINK REF="REF-Shaikh-2012" TYPE="REFERENCE">Shaikh 2012</LINK>). Recent practice guidelines for the diagnosis and management of rhinosinusitis suggest considering the use of INCS as adjunctive therapy (<LINK REF="REF-Slavin-2005" TYPE="REFERENCE">Slavin 2005</LINK>; <LINK REF="REF-Spector-1998" TYPE="REFERENCE">Spector 1998</LINK>). Although the guidelines reflect the belief of many clinicians that INCS are a valuable component of rhinosinusitis management, limited clinical data are available on their use in this disease. A recent experimental prospective study on rabbits with surgically introduced sinusitis demonstrated no clear advantage of steroids in the treatment of sinus infections using this model (<LINK REF="REF-Cable-2000" TYPE="REFERENCE">Cable 2000</LINK>). The use of adjunctive medications for acute sinusitis such as antihistamines, decongestants and nasal steroids also remains controversial (<LINK REF="REF-Shrum-2001" TYPE="REFERENCE">Shrum 2001</LINK>). Several recent studies tested the effectiveness of inhaled steroids for relieving symptoms in acute sinusitis in humans, concluding that this treatment is effective. A systematic review that addresses the effectiveness of this therapy will provide useful information to all primary care practitioners and could assist in formulating the best treatment plan for the individual patient.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-20 10:08:57 +1000" MODIFIED_BY="[Empty name]">
<P>We examined whether intranasal corticosteroids (INCS) are effective in relieving symptoms of acute sinusitis in adults and children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-20 10:32:52 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_STUDIES MODIFIED="2011-04-20 07:58:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing topical intranasal steroids with placebo or no intervention.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-06-15 07:02:05 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Children and adults, irrespective of age, with acute sinusitis.</LI>
<LI>Acute sinusitis is defined by clinical diagnosis and nasal endoscopy or radiological evidence or nasal endoscopy.</LI>
<LI>We included trials including a mixed population of acute and non-acute sinusitis if outcomes were reported separately for these subgroups.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-20 10:32:52 +1000" MODIFIED_BY="[Empty name]">
<P>Studies which used intranasal corticosteroids (INCS) - any preparation, dose or route of administration (for example, inhaled or drops) versus placebo or no intervention in the control group. We included trials reporting combined interventions only if the control arm received the same co-treatments as the intervention arm, except for topical steroids.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-06-15 07:02:13 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-06-15 07:02:10 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Proportion of participants with resolution or improvement of symptoms.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-06-15 07:02:13 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Any adverse event that necessitated discontinuation of treatment.</LI>
<LI>Proportion of participants that developed complications.</LI>
<LI>Drop-outs before the end of the study.</LI>
<LI>Rates of relapse in symptoms.</LI>
<LI>Proportion of participants that returned to school or work within a specific time frame.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-27 20:59:13 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-11-27 20:59:13 +1000" MODIFIED_BY="[Empty name]">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 4, part of <I>The Cochrane Library</I>,<I> </I>www.thecochranelibrary.com (accessed 22 May 2013), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (April 2011 to May week 2, 2013) and EMBASE (April 2011 to May 2013). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of previous searches.</P>
<P>We searched MEDLINE and CENTRAL using the following search strategy. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the strategy to search EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (OVID)</HEADING>
<P>1 exp Sinusitis/<BR/>2 sinusit*.tw.<BR/>3 (rhinosinusit* or nasosinusit*).tw.<BR/>4 or/1-3<BR/>5 exp Steroids/<BR/>6 steroid*.tw.<BR/>7 exp Adrenal Cortex Hormones/<BR/>8 adrenal cortex hormone*.tw.<BR/>9 exp Anti-Inflammatory Agents/<BR/>10 anti-inflammat*.tw.<BR/>11 corticosteroid*.tw.<BR/>12 or/5-11<BR/>13 exp Administration, Intranasal/<BR/>14 exp Administration, Topical/<BR/>15 (nasal* or intranasal* or topical*).tw.<BR/>16 or/13-15<BR/>17 12 and 16<BR/>18 4 and 17</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-08-29 09:21:00 +1000" MODIFIED_BY="[Empty name]">
<P>We inspected the reference lists in all identified studies for further relevant studies. We also scrutinised the existing review literature (for example, <LINK REF="REF-Mucha-2003" TYPE="REFERENCE">Mucha 2003</LINK>). We contacted trial authors for information about possible unpublished studies. There were no language or publication restrictions. We also searched the WHO ICTRP and ClinicalTrials.gov trials registries (14 May 2013) for completed and ongoing trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-04-20 08:03:27 +1000" MODIFIED_BY="[Empty name]">
<P>The two review authors independently reviewed the abstracts of potential studies to be included in the review. We obtained the full article and independently inspected it for relevance.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="Liz Dooley">
<P>The two review authors independently extracted data from included trials. We documented disagreements and resolved them by discussion. We contacted the trial authors for clarification when necessary. We also documented justification for excluding studies from the review in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. We reported on the following domains.</P>
<OL>
<LI>Characteristics of trials: publication status, year, country of study, setting, design, inclusion and exclusion criteria, recruitment, methods, analysis, results.</LI>
<LI>Characteristics of participants: study population, number of participants in each group, age, gender, nationality, diagnostic criteria.</LI>
<LI>Characteristics of interventions: preparation used, dose, length of treatment and follow-up, compliance, co-interventions.</LI>
<LI>Outcomes: resolution of symptoms, improvement of symptoms, relapse, complications, return to school/work, adverse events related to the intervention, drop-outs before the end of the study and reasons for dropping out.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-14 22:19:33 +1000" MODIFIED_BY="[Empty name]">
<P>The two review authors independently assessed the methodological quality of each study in the 'Risk of bias' tables, as outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<OL>
<LI>random sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding of participants and personnel;</LI>
<LI>blinding of outcome assessment;</LI>
<LI>incomplete out come data;</LI>
<LI>selective reporting; and</LI>
<LI>other bias.</LI>
</OL>
<P>We included trials if they met the following criteria: randomisation method described that would not allow the investigator/participant to know or influence intervention group before the eligible participant entered in the study (low risk of bias) and randomisation stated but no information on method used is available (moderate risk of bias). There were no disagreements and we observed no selective reporting or other potential bias. We obtained additional information from the trial authors when the publications presented insufficient detail.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-27 21:47:17 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed dichotomous data by calculating the risk ratio (RR) and risk difference (RD) for each trial with the uncertainty in each result being expressed as 95% confidence interval (CI). We expressed the results using the approach recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We performed all analyses on the basis of intention-to-treat (ITT). We divided study data as far as possible from published and unpublished information into subgroups for children less than 18 years, adults and co-interventions. We planned subgroup analyses to assess the impact of these possible sources of heterogeneity. We used the fixed-effect model for combining studies in the absence of heterogeneity.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-05-26 09:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>We included RCTs with standard designs and parallel groups in the review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-04-20 09:33:22 +1000" MODIFIED_BY="[Empty name]">
<P>We tried to contact study authors for missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-05-26 09:32:55 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity by inspection of the graphical presentations and I<SUP>2 </SUP>statistic for heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-05-26 09:33:52 +1000" MODIFIED_BY="[Empty name]">
<P>We did not have sufficient studies for performing funnel plot analysis to assess possible publication bias. We did not observe other reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-05-26 09:34:24 +1000" MODIFIED_BY="[Empty name]">
<P>We did not find any evidence of heterogeneity between studies as assessed by inspection of the graphical presentations; therefore we used the fixed-effect model for combining the studies.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-05-26 09:35:03 +1000" MODIFIED_BY="[Empty name]">
<P>We did not perform the planned subgroup analyses as the included studies did not report data for these subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-06-14 21:44:09 +1000" MODIFIED_BY="[Empty name]">
<P>We planned no sensitivity analyses in the absence of heterogeneity.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-20 10:37:50 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-20 10:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>We did not identify any trials to include or exclude in this 2013 update from the 82 new references identified. In the previous review (<LINK REF="REF-Zalmanovici-Trestioreanu-2011" TYPE="REFERENCE">Zalmanovici Trestioreanu 2011</LINK>) 495 references were identified and the abstracts were inspected by the two review authors.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-08-20 10:36:30 +1000" MODIFIED_BY="[Empty name]">
<P>Four studies with 1943 participants assigned to intranasal corticosteroids (INCS) or placebo met the inclusion criteria for this review. Three studies were multicentre trials; one was conducted at 22 sites - 12 primary care and 10 otolaryngology clinics (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>), one study involved outpatients from 61 treatment centres in the USA (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>), one study was conducted at 71 medical centres in 14 countries (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>) and one study involved participants from the Marmara University Hospital Pediatric Outpatient Clinic (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>).</P>
<P>One trial had three treatment arms; two arms for different doses of INCS and one arm for placebo (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). One trial had four treatment arms; two arms for different doses of INCS, one arm for antibiotic and one arm for placebo (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>). We performed meta-analyses for treatment arms using different doses of INCS combined and separately.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Participants included in the trials were children and adults with a documented episode of acute sinusitis, confirmed by radiology or nasal endoscopy. The entry criteria in the trials were similar.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>All the studies used a placebo in the control group. Participants in the treatment groups in three studies received INCS for 21 days as fluticasone propionate two puffs daily in each nostril, giving a total dose of 200 µg (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>), MFNS (mometasone furoate) twice daily giving a total dose of 400 µg or 800 µg (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>) and budesonide 50 µg twice daily to each nostril as a nasal spray (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>) as adjuvant therapy to antibiotics. One study used MFNS 200 µg and 400 µg total daily dose in the treatment arms for 15 days as monotherapy (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>). Other concomitant therapies were similar in all groups, in every study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The included studies reported the proportion of participants with clinical success; the length of time until clinical success; difference over time in sinusitis symptoms; quality of life scores; relapse (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>); improvement in total and individual symptoms scores; onset of relief and evaluation of changes in computerised tomography (CT) sinus scans (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>); difference in weekly symptom scores as difference between groups or change from baseline (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>); global response to treatment; time to onset of action; mean major symptom scores; mean total symptom scores; individual symptom scores; treatment failure and disease recurrence (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>). Information on adverse events that occurred during the trials is presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Drop-outs before the end of the study and the reasons for leaving were described in all the studies. One study did not report separate data for the groups for this outcome and the number of participants initially randomised in each group had a high drop-out rate. It reported results as medians of scores using non-parametric tests because a wide range of scores were without normal distribution; it was not included in the meta-analyses (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-20 10:37:50 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded 491 studies for one or more of the following reasons: not acute sinusitis; not randomised; observational studies; intervention of interest not used; no relevant outcomes reported; repeated reports of the same study; and review articles. Thirteen reports were considered potentially eligible for inclusion but after inspection of the full papers, we excluded nine (<LINK REF="STD-Bachert-2007" TYPE="STUDY">Bachert 2007</LINK>; <LINK REF="STD-Gehanno-2000" TYPE="STUDY">Gehanno 2000</LINK>; <LINK REF="STD-Jurkiewicz-2004" TYPE="STUDY">Jurkiewicz 2004</LINK>; <LINK REF="STD-Meltzer-1993" TYPE="STUDY">Meltzer 1993</LINK>; <LINK REF="STD-Meltzer-2000" TYPE="STUDY">Meltzer 2000</LINK>; <LINK REF="STD-Quarnberg-1992" TYPE="STUDY">Quarnberg 1992</LINK>; <LINK REF="STD-Tutkun-1996" TYPE="STUDY">Tutkun 1996</LINK>; <LINK REF="STD-Williamson-2007" TYPE="STUDY">Williamson 2007</LINK>; <LINK REF="STD-Yilmaz-2000" TYPE="STUDY">Yilmaz 2000</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). In the first publication of this review (<LINK REF="REF-Zalmanovici-2007" TYPE="REFERENCE">Zalmanovici 2007</LINK>) two studies were awaiting further assessment for missing data (<LINK REF="STD-Meltzer-2000" TYPE="STUDY">Meltzer 2000</LINK>; <LINK REF="STD-Tutkun-1996" TYPE="STUDY">Tutkun 1996</LINK>). We excluded these studies in the first update (<LINK REF="REF-Zalmanovici-2009" TYPE="REFERENCE">Zalmanovici 2009</LINK>) as data were not made available from the trial authors, whom we contacted. The reasons for exclusion are added to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. In addition, for one study (<LINK REF="STD-Jurkiewicz-2004" TYPE="STUDY">Jurkiewicz 2004</LINK>), no abstract or full paper was available.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>The studies were well-designed, randomised, double-blind, placebo-controlled trials. The overall risk of bias is presented graphically in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2011-04-20 08:44:07 +1000" MODIFIED_BY="[Empty name]">
<P>All four studies were RCTs. However, only two contained an adequate report of the generation of allocation sequence (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>; <LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>) and one study reported concealment of allocation (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>). The assessment for trial inclusion was based on allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-03-02 08:43:17 +1000" MODIFIED_BY="Liz Dooley">
<P>The trials were double-blinded and the method of blinding was adequate. One study did not describe the method of blinding (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs before the end of the study and the reasons for leaving were described in the studies. The total loss to follow-up was 7% (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>), 11% (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>), 10% (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>) and 41% (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>), respectively.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-06-14 21:49:39 +1000" MODIFIED_BY="[Empty name]">
<P>The studies reported what was pre-stated in their protocol.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-06-14 21:49:48 +1000" MODIFIED_BY="[Empty name]">
<P>We identified no other sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Four studies that included 1943 participants met our inclusion criteria (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>; <LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>; <LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). Two studies had more than two arms, two treatment arms for different doses of intranasal corticosteroids (INCS), and we performed separate and combined dose meta-analyses (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). One study was included in the review but not in the meta-analysis as it was not possible to extract data, non-parametric tests were used and it had a high drop-out rate (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with resolution or improvement of symptoms</HEADING>
<P>Information on our primary outcome was found in three trials, assessed at 15 days in one study (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>) and at 21 days in two other studies (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). When combined using intention-to-treat (ITT) analysis, 73% of INCS-treated participants and 66.4% of controls had resolution or marked improvement of symptoms (for every 100 patients treated with INCS seven additional patients had complete or marked symptom relief). Individuals treated with INCS (combined results for the 200 µg, 400 µg and 800 µg doses) were more likely to have complete relief or improvement than the placebo group (risk ratio (RR) 1.11; 95% confidence interval (CI) 1.04 to 1.18) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>); (risk difference (RD) 0.07; 95% CI 0.03 to 0.11) and this result was statistically significant. When we performed separate meta-analyses for different doses of INCS, a stronger and statistically significant effect was obtained when patients were treated with 400 µg than 200 µg mometasone furoate (MFNS) total daily dose (RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% CI 0.98 to 1.11) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>); (RD 0.06; 95% CI 0.02 to 0.11 versus RD 0.04; CI 95% -0.02 to 0.09). The attributable risk percentage (AR%) calculated for the results that were statistically significant means that 8% (one in 12) of all patients who, having received the 400 µg dose of INCS, had resolution or improvement in symptoms could attribute that relief to the treatment. When calculated from results combined across all doses, the number is 9% (one in 11). One study that used in one of the treatment arms an 800 µg MFNS daily dose found a statistically significant effect for this dose (RR 1.21; 95% CI 1.05 to 1.39) (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Any adverse event that necessitated discontinuation of treatment</HEADING>
<P>This outcome was reported in two studies (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). No separate data for each treatment arm were available in one study (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>) and the participants were equally distributed among the three arms. One study reported a drop-out rate from treatment of 1%, 3%, 2% and 2% because of adverse events in the INCS 200 µg, 400 µg, antibiotic and placebo arms (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants that developed complications</HEADING>
<P>No studies reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drop-outs before the end of the study</HEADING>
<P>This outcome is reported in three studies (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>; <LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>). No statistically significant difference could be found for participants that were lost to follow-up in the two groups (RR 0.85; 95% CI 0.64 to 1.12) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Using a higher dose of INCS did not change the results (RR 0.86; 95% CI 0.61 to 1.20) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) for MFNS 400 µg versus MFNS 200 µg (RR 0.75; 95% CI 0.46 to 1.21) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rates of relapse in symptoms</HEADING>
<P>Two studies reported data for this outcome (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>; <LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>). No statistically significant differences could be found between groups; 6.3% and 10% had relapse in the INCS and placebo groups (RR 0.71; 95% CI 0.44 to 1.15) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The median time to first recurrence was three days earlier in the placebo group (22 versus 25 days) in one study (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>). One study did not find significant differences between groups for different doses of INCS (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants that returned to school or work within a specific time frame</HEADING>
<P>No studies reported this outcome. One study (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>) reported a higher subjective level of work performance that was significantly different on day 21 (P value = 0.009) in the INCS treatment group versus placebo. The difference between groups with respect to the total number of hours missed from work was not significant (P value = 0.40).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Acute sinusitis is typically first seen as an upper respiratory tract infection that has persisted beyond five to seven days. The diagnosis of sinusitis is based on a combination of clinical history with physical examination, nasal cytology or imaging studies (or both). Factors that may predispose to sinusitis include allergic or occupational rhinitis, vasomotor rhinitis, nasal polyps, rhinitis medicamentosa and immunodeficiency (<LINK REF="REF-Spector-1998" TYPE="REFERENCE">Spector 1998</LINK>). Although acute sinusitis is an infectious disease in which several bacterial species play a major aetiological role, there is an important interaction between respiratory viruses (for example, common cold viruses) and bacteria in the pathogenesis of acute community-acquired sinusitis (<LINK REF="REF-Winther-1990" TYPE="REFERENCE">Winther 1990</LINK>). Upper respiratory tract infections and allergic inflammation are recognised as the important risk factors for acute sinusitis, with upper respiratory tract infection being the most common (<LINK REF="REF-Wald-1988" TYPE="REFERENCE">Wald 1988</LINK>).</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Four studies met the inclusion criteria in our review. They were well-conducted and produced results that suggest a clinically relevant, earlier resolution of symptoms in participants treated with intranasal corticosteroids (INCS), without the risk of severe adverse events, even when higher doses in the therapeutic range were used. All four of the trials reached statistical significance for this outcome. One in 12 of all patients who having received the 400 µg dose had resolution or improvement in symptoms could attribute that relief to the treatment. Across all doses, the number is one in 11. No statistically significant difference in the relapse rate between groups was found. One study (<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>) found that INCS may be a useful ancillary treatment to antibiotics in childhood sinusitis and effective in reducing the cough and nasal discharge earlier in the course of acute sinusitis. Clinical signs and symptoms decreased significantly in both groups in comparison to baseline (P &lt; 0.01) and in the intervention group when compared to placebo in the scores for cough and nasal discharge at the end of the second week (P &lt; 0.05). This study was not included in the meta-analyses as it had a high drop-out rate (41%), drop-outs were not described separately for both groups, outcomes were reported as weekly scores using non-parametric tests and it was not possible to extract data for our outcomes. One of the included studies (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>) found a significant improvement in the total symptom score and in individual symptom scores during the treatment period.</P>
<P>The mean change in the score from computerised tomography (CT) scans of the sinuses from baseline to day 21 was not statistically significant between the treatment and control groups. One other included study (<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>) found the median number of days to clinical success in those treated with INCS was six days compared to nine and a half days in those treated with a placebo. The subjective level of work performance at 21 days was significantly better in the treatment group. Improvement in sinusitis symptoms scores, sinusitis-related quality of life and the total number of hours of work missed were not significantly different in the two groups. Mometasone furoate (MFNS) 400 µg daily demonstrated significant superiority over MFNS 200 µg daily in nasal congestion/stuffiness score (P = 0.013) and global response to treatment (P = 0.002) was more consistently superior across the endpoints and over amoxicillin in one study (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>), suggesting that higher doses are needed. Also, this study found significant improvement in the major symptom score (P &lt; 0.001), total symptom score (P &lt; 0.001), global response to treatment (P = 0.001) and individual symptom scores (rhinorrhoea, nasal congestion/stuffiness, sinus headache, facial pain) for MFNS 400 µg over placebo.</P>
<P>The results of these studies and reviews support the current clinical rationale of adding an INCS to antibiotic therapy for acute episodes of rhinosinusitis and suggest that higher doses are needed; effectiveness as monotherapy remains to be demonstrated by further studies. The included studies enrolled adults and children and the samples were representative of participants that physicians would recognise as common in their practice. Clinical improvement was assessed by patient-derived (subjective) symptom reports and this outcome met one of our study goals: evaluating alleviation of symptoms together with possible adverse events.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-06-14 21:57:52 +1000" MODIFIED_BY="[Empty name]">
<P>It is important that the mucous membranes and ciliary function are restored to normal as soon as possible, to avoid recurrence or development of chronic sinusitis (<LINK REF="STD-Quarnberg-1992" TYPE="STUDY">Quarnberg 1992</LINK>). Two surveys of primary care and specialty physicians suggested considerable variability in approaches to treatment (<LINK REF="REF-Piccirillo-2001" TYPE="REFERENCE">Piccirillo 2001</LINK>; <LINK REF="REF-Williams-1993" TYPE="REFERENCE">Williams 1993</LINK>). Recommendations for appropriate treatment for acute sinusitis range from symptomatic treatment alone (<LINK REF="REF-Snow-2001" TYPE="REFERENCE">Snow 2001</LINK>) to a prolonged course of antibiotic therapy (<LINK REF="REF-Winther-1990" TYPE="REFERENCE">Winther 1990</LINK>). A variety of ancillary treatments aimed at improving nasal and sinus ostial patency (antihistamines, decongestants, INCS and nasal irrigation) might be helpful in the treatment of sinusitis but there are few controlled studies to support or deny their effectiveness (<LINK REF="REF-Zeiger-1992" TYPE="REFERENCE">Zeiger 1992</LINK>). Numerous clinical trials attest to the efficacy of topical corticosteroids in controlling symptoms of allergic rhinitis (<LINK REF="REF-Juniper-1990" TYPE="REFERENCE">Juniper 1990</LINK>; <LINK REF="REF-Seigel-1988" TYPE="REFERENCE">Seigel 1988</LINK>). The similarity of the respiratory epithelium in the nose and paranasal sinuses, as well as the contiguity of these areas, would lead one to expect that sinusitis might also be treatable with inhaled corticosteroids.</P>
<P>Whether nasal steroid therapy can sufficiently decrease nasal inflammation and improve mucociliary transport to the point where the ostiomeatal complex becomes competent is unknown. Topical corticosteroids offer the theoretical advantage of a localised therapeutic action in nasal tissues, without the occurrence of undesirable systemic effects (<LINK REF="REF-Sahay-1980" TYPE="REFERENCE">Sahay 1980</LINK>). Inhaled corticosteroids have been used safely in patients with allergic rhinitis or asthma. There exists a theoretical concern regarding the potential spread of infection in acute sinusitis. However, this does not occur when topical corticosteroids are administered concurrently with antibiotics (<LINK REF="REF-Druce-1990" TYPE="REFERENCE">Druce 1990</LINK>; <LINK REF="REF-Druce-1991" TYPE="REFERENCE">Druce 1991</LINK>). Investigations of whether INCS promotes resolution of symptoms and prevents recurrences of sinusitis have yielded conflicting results (<LINK REF="STD-Meltzer-1993" TYPE="STUDY">Meltzer 1993</LINK>; <LINK REF="STD-Quarnberg-1992" TYPE="STUDY">Quarnberg 1992</LINK>).</P>
<P>Acute sinusitis is a very common infection in childhood but its management remains a controversial issue. A considerable proportion of children, especially those with mild or improving symptoms, may not have to be treated at all (<LINK REF="REF-Contopoulos-2003" TYPE="REFERENCE">Contopoulos 2003</LINK>). Management of acute sinusitis usually includes an oral antibiotic. However, it has been estimated that about 45% of cases will resolve without antibiotics (<LINK REF="REF-Spector-1998" TYPE="REFERENCE">Spector 1998</LINK>).</P>
<P>Considering the host of symptoms associated with acute rhinosinusitis, recovery can take time and be of substantial discomfort to the affected patient. The burden of affected individuals in terms of decreased productivity, absenteeism from the workplace and diminished quality of life, when added to the cost of care and the growing public health menace of antibiotic-resistant bacteria, makes rhinosinusitis a serious disease that warrants a precise diagnosis and effective therapy. Recognised pitfalls in acute rhinosinusitis management are the injudicious use of antibiotics and antihistamines (<LINK REF="REF-Winstead-2003" TYPE="REFERENCE">Winstead 2003</LINK>). The decision on the best treatment for the specific patient should be based on the severity of symptoms, adapted individually, taking in consideration the existing evidence and the patient's preferences.</P>
<P>Most clinicians diagnose acute sinusitis using only clinical symptoms, without additional diagnostic tests. Over-diagnosis of acute bacterial rhinosinusitis is not surprising, considering the lack of specific clinical features that distinguish it from non-bacterial upper respiratory tract infections. Often, patients and physicians believe that an upper respiratory tract infection has gone on too long and that antibiotic treatment is therefore needed. Symptomatic treatment and reassurance are the preferred initial management strategy for patients with mild symptoms. Antibiotic therapy should be reserved for patients with severe symptoms who meet the criteria for the clinical diagnosis of acute bacterial rhinosinusitis, regardless of the duration of the illness. The greatest barrier to efficient antibiotic treatment of acute bacterial rhinosinusitis is the lack of a simple and accurate diagnostic test. Until a better test is widely available in clinical practice, the primary diagnosis of acute bacterial rhinosinusitis will remain imprecise (<LINK REF="REF-Snow-2001" TYPE="REFERENCE">Snow 2001</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-06-14 21:58:08 +1000" MODIFIED_BY="[Empty name]">
<P>Currently, nasal steroid therapy has become an acceptable adjunct in treating both acute and chronic sinusitis. Several intranasal steroids are now available: flunisolide, beclomethasone, triamcinolone, fluticasone, budesonide and mometasone. Each of these has proven to be effective in the treatment of allergic rhinitis and may be a useful addition in sinus disease (<LINK REF="REF-Spector-1998" TYPE="REFERENCE">Spector 1998</LINK>). The <I>International Consensus Conference Proceedings on Rhinitis</I> recommends the use of INCS as a first-line therapy, since they have been found to be well-tolerated and effective with minimal adverse events (<LINK REF="REF-Gawchik-2000" TYPE="REFERENCE">Gawchik 2000</LINK>).</P>
<P>The evidence available suggests that some intranasal steroids, such as beclomethasone dipropionate, may slow growth when used regularly for prolonged periods (<LINK REF="REF-Allen-2000" TYPE="REFERENCE">Allen 2000</LINK>). Studies of MFNS in adults and children with allergic rhinitis showed a lack of hypothalamic-pituitary axis suppression, no childhood growth suppression and were consistent with extremely low bioavailability of MFNS after intranasal administration (<LINK REF="REF-Brannan-1997" TYPE="REFERENCE">Brannan 1997</LINK>; <LINK REF="REF-Davies-1997" TYPE="REFERENCE">Davies 1997</LINK>; <LINK REF="REF-Schenkel-2000" TYPE="REFERENCE">Schenkel 2000</LINK>). Reducing the systemic activity of nasal corticosteroids to the lowest possible level is desirable. Pharmacologically, newer drugs such as MFNS and fluticasone propionate appear to have substantially higher topical potencies, higher lipid solubilities and lower systemic bioavailabilities than older compounds. With respect to adverse events, emerging data suggest that MFNS and fluticasone may have less potential for systemic effects during prolonged use, particularly in children (<LINK REF="REF-Corren-1999" TYPE="REFERENCE">Corren 1999</LINK>). For short-term therapy of one to two months, the first-generation INCS (beclomethasone, triamcinolone, budesonide and flunisolide) could be used and MFNS and fluticasone (second-generation drugs) could be considered for long-term therapy. With the exception of fluticasone for children aged four years and older and MFNS for those aged three years and older, the other INCS including beclomethasone, triamcinolone, budesonide and flunisolide are approved for children six years and older. All are effective, so the major considerations are cost and safety (<LINK REF="REF-Galant-2001" TYPE="REFERENCE">Galant 2001</LINK>).</P>
<P>The decision on the best treatment for the specific patient should be based on the severity of symptoms, adapted individually, taking in consideration the existing evidence and the patient's preferences.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-04-20 04:36:08 +1000" MODIFIED_BY="[Empty name]">
<P>A small number of studies were included in this review and not all reported an adequate concealment of allocation to treatment.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-06-14 21:58:18 +1000" MODIFIED_BY="[Empty name]">
<P>The minor effects of inhaled corticosteroids for acute sinusitis observed in this review are supported by other existing evidence, including the evidence mentioned here.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-11-27 21:22:30 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-11-27 21:22:30 +1000" MODIFIED_BY="[Empty name]">
<P>Current evidence supports the use of intranasal corticosteroids for relief or improvement in clinical outcomes in acute uncomplicated sinusitis, although data are limited and modest effects were observed. There is no evidence that their use as a monotherapy or as an adjuvant therapy would be detrimental in therapeutic doses. The study population included in this review was diagnosed both clinically and by radiology or endoscopy and is not necessarily identical to the participants from the clinical practice where the diagnosis is usually based on clinical signs and symptoms alone.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-06-17 10:58:53 +1000" MODIFIED_BY="[Empty name]">
<P>Given the small number of trials, additional large, randomised, placebo-controlled trials are needed to evaluate the efficacy of intranasal corticosteroids for acute sinusitis. These trials should describe adequate allocation and concealment procedures, be double-blinded and include outcomes on work performance, return to work and functional status, as well as assessment of different doses of INCS, the optimal duration of treatment and the risk-benefit ratio. Studies on participants with milder forms of acute sinusitis receiving symptomatic treatment including INCS and without antibiotic therapy could also be conducted, taking into consideration the emergence of resistant organisms and adverse events that result from the irrational use of antibiotics.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Thanks to the Cochrane Acute Respiratory Infections Group for ongoing assistance, especially Chanpen Choprapawon, Leonard Leibovici, Marilyn Oates, Richmal Oates-Whitehead and Erik Schenkel for useful comments on the draft protocol. We wish to thank Chanpen Choprapawon, Eric Schenkel, Richard G. Shoemaker and Leonard Leibovici for the commenting on the draft review and Liz Dooley and Sarah Thorning for the suggested search strategy and support with the searches and updates. We also wish to thank Yusra Adel Badr, JM Klossek, Sree Nair and<B> </B>Nick Matheson for commenting on the 2009 updated draft and Clalit Health Services Tel-Aviv district for supporting the activities of Anca Zalmanovici.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-20 13:02:33 +1000" MODIFIED_BY="[Empty name]">
<P>Dr Anca Zalmanovici wrote the review, searched the literature, selected the studies to be included, assessed their quality, entered the data into <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>, wrote the methods, results and discussion sections and updated the review.<BR/>Dr John Yaphe searched the literature, was an independent assessor in selecting trials to be included, assessed the quality of the trials, wrote the discussion section and edited the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>We thank Professor Leonard Leibovici from the Rabin Medical Center and Professor Michael A Weingarten, of the Department of Family Medicine, Tel-Aviv University, for their useful suggestions and final revision of this review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-06-14 22:09:35 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-06-14 22:09:12 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barlan-1997" MODIFIED="2011-06-14 22:09:02 +1000" MODIFIED_BY="[Empty name]" NAME="Barlan 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-06-14 22:09:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlan IB, Erkan E, Bakir M, Berrak S, Basaran MM</AU>
<TI>Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1997</YR>
<VL>78</VL>
<PG>598-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolor-2001" MODIFIED="2011-06-14 22:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Dolor 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-06-14 22:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolor RJ, Witsell DL, Hellkamp AS, Williams JW, Califf RM, Simel DL</AU>
<TI>Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>3097-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2005" NAME="Meltzer 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Meltzer EO, Bachert C , Staudinger H - Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin and placebo.&lt;br&gt; Journal of Allergy and Clinical Immunology 116(6): 1289-95 Dec 2005&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer EO, Bachert C, Staudinger H</AU>
<TI>Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin and placebo</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>6</NO>
<PG>1289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nayak-2002" MODIFIED="2011-06-14 22:09:12 +1000" MODIFIED_BY="[Empty name]" NAME="Nayak 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-14 22:09:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nayak AS, Settipane GA, Pedinoff A, Charous BL, Meltzer EO, Busse WW, et al</AU>
<TI>Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<PG>271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-06-14 22:09:35 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bachert-2007" MODIFIED="2011-04-20 07:09:50 +1000" MODIFIED_BY="[Empty name]" NAME="Bachert 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-04-20 07:09:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachert C, Meltzer EO</AU>
<TI>Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis</TI>
<SO>Rhinology</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>3</NO>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gehanno-2000" MODIFIED="2011-06-14 22:09:17 +1000" MODIFIED_BY="[Empty name]" NAME="Gehanno 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-06-14 22:09:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gehanno P, Beauvillain C, Bobin S, Chobaut JC, Desaulty A, Dubreuil C, et al</AU>
<TI>Short therapy with amoxicillin-clavulanate and corticosteroids in acute sinusitis: results of a multicentre study in adults</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>679-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jurkiewicz-2004" MODIFIED="2008-12-28 03:33:13 +1000" MODIFIED_BY="[Empty name]" NAME="Jurkiewicz 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-28 03:33:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jurkiewicz D, Zielnik-Jurkiewicz B</AU>
<TI>Intranasal corticosteroid in the treatment of acute sinusitis</TI>
<SO>5th European Congress of Oto-Rhino-Laryngology Head and Neck Surgery (EUFOS)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-1993" MODIFIED="2011-06-14 22:09:22 +1000" MODIFIED_BY="[Empty name]" NAME="Meltzer 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-06-14 22:09:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer EO, Orgel HA, Backhaus JW, Busse WW, Druce HM, Metzger J, et al</AU>
<TI>Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>812-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2000" MODIFIED="2011-04-20 07:11:14 +1000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-04-20 07:11:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR, et al</AU>
<TI>Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>106</VL>
<PG>630-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quarnberg-1992" MODIFIED="2011-06-14 22:09:28 +1000" MODIFIED_BY="[Empty name]" NAME="Quarnberg 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-06-14 22:09:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quarnberg Y, Kantola O, Salo J, Toivanen M, Valtonen H, Vuori E</AU>
<TI>Influence of topical steroid treatment on maxillary sinusitis</TI>
<SO>Rhinology</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>103-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tutkun-1996" MODIFIED="2008-12-28 03:33:46 +1000" MODIFIED_BY="[Empty name]" NAME="Tutkun 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-12-28 03:33:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tutkun A, Inanli S, Batman C, Uneri C, Sehitoglu MA</AU>
<TI>The impact of intranasal steroid as an adjunct to therapy for sinusitis</TI>
<SO>Marmara Medical Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>1</NO>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williamson-2007" MODIFIED="2009-03-02 08:37:14 +1000" MODIFIED_BY="Liz Dooley" NAME="Williamson 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-02 08:37:14 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson IG, Rumsby K, Benge S, Moore M, Smith PW, Cross M, et al</AU>
<TI>Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>21</NO>
<PG>2487-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yilmaz-2000" MODIFIED="2011-06-14 22:09:35 +1000" MODIFIED_BY="[Empty name]" NAME="Yilmaz 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-06-14 22:09:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yilmaz G, Varan B, Yilmaz T, Gurakan B</AU>
<TI>Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children</TI>
<SO>European Archives of Oto-rhino-laryngology</SO>
<YR>2000</YR>
<VL>257</VL>
<NO>5</NO>
<PG>256-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-12-28 03:33:46 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ahovuo_x002d_Saloranta-2011" MODIFIED="2011-05-07 14:05:11 +1000" MODIFIED_BY="[Empty name]" NAME="Ahovuo-Saloranta 2011" TYPE="COCHRANE_REVIEW">
<AU>Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams Jr JW, Makela M</AU>
<TI>Antibiotics for acute maxillary sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-05-07 14:05:11 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-05-07 14:05:11 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000243.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Allen-2000" NAME="Allen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Allen DB</AU>
<TI>Do intranasal corticosteroids affect childhood growth?</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>Suppl 62</NO>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-2003" MODIFIED="2011-06-14 22:09:50 +1000" MODIFIED_BY="[Empty name]" NAME="Becker 2003" TYPE="JOURNAL_ARTICLE">
<AU>Becker DG</AU>
<TI>Medical treatment of sinusitis</TI>
<SO>Journal of Long-term Effects of Medical Implants</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>3</NO>
<PG>195-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benninger-1997" MODIFIED="2011-06-14 22:09:59 +1000" MODIFIED_BY="[Empty name]" NAME="Benninger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Benninger MS, Anon J, Mabry RL</AU>
<TI>The medical management of rhinosinusitis</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1997</YR>
<VL>117</VL>
<NO>3 Pt 2</NO>
<PG>S41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brannan-1997" NAME="Brannan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brannan MD, Herron JM, Affrime MB</AU>
<TI>Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>1330-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cable-2000" MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]" NAME="Cable 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cable BB, Wassmuth Z, Mann EA, Hommer D, Connely G, Klem C, et al</AU>
<TI>The effect of corticosteroids in the treatment of experimental sinusitis</TI>
<SO>American Journal of Rhinology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Contopoulos-2003" NAME="Contopoulos 2003" TYPE="JOURNAL_ARTICLE">
<AU>Contopoulos-Ioannidis DG, Ioannidis JP, Lau J</AU>
<TI>Acute sinusitis in children: current treatment strategies</TI>
<SO>Paediatric Drugs</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>71-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corren-1999" NAME="Corren 1999" TYPE="JOURNAL_ARTICLE">
<AU>Corren J</AU>
<TI>Intranasal corticosteroids for allergic rhinitis: how do different agents compare?</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>4 Pt 1</NO>
<PG>S144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1997" NAME="Davies 1997" TYPE="JOURNAL_ARTICLE">
<AU>Davies RJ, Nelson HS</AU>
<TI>Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>27-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Druce-1990" MODIFIED="2011-06-14 22:10:08 +1000" MODIFIED_BY="[Empty name]" NAME="Druce 1990" TYPE="JOURNAL_ARTICLE">
<AU>Druce HM</AU>
<TI>Adjuncts to medical management of sinusitis</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1990</YR>
<VL>103</VL>
<PG>880-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Druce-1991" NAME="Druce 1991" TYPE="JOURNAL_ARTICLE">
<AU>Druce HM, Slavin RG</AU>
<TI>Sinusitis: critical need for further study</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>675-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galant-2001" NAME="Galant 2001" TYPE="JOURNAL_ARTICLE">
<AU>Galant SP, Wilkinson R</AU>
<TI>Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>7</NO>
<PG>453-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gawchik-2000" NAME="Gawchik 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gawchik SM, Saccar CL</AU>
<TI>A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis</TI>
<SO>Drug Safety</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>4</NO>
<PG>309-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-1994" MODIFIED="2011-04-20 07:12:19 +1000" MODIFIED_BY="[Empty name]" NAME="Gwaltney 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gwaltney JM, Phillips CD, Miller RD, Riker DK</AU>
<TI>Computed tomographic study of the common cold</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-1995" NAME="Gwaltney 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gwaltney JM Jr, Jones JG, Kennedy DW</AU>
<TI>Medical management of sinusitis: educational goals and management guidelines: the International Conference on Sinus Disease</TI>
<SO>Annals of Otology, Rhinology and Laryngology Supplement</SO>
<YR>1995</YR>
<VL>167</VL>
<PG>22-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-11-27 21:39:20 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juniper-1990" NAME="Juniper 1990" TYPE="JOURNAL_ARTICLE">
<AU>Juniper EF, Guyatt GH, O'Byrne PM, Viveiros M</AU>
<TI>Aqueous beclomethasone dipropionate nasal spray: regular versus "as required" use in the treatment of seasonal allergic rhinitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1990</YR>
<VL>86</VL>
<PG>380-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaliner-1997" MODIFIED="2011-04-20 07:14:27 +1000" MODIFIED_BY="[Empty name]" NAME="Kaliner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kaliner MA, Osguthorpe JD, Fireman P, Anon J, Georgitis J, Davis ML, et al</AU>
<TI>Sinusitis: bench to bedside. Current findings, future directions</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>Suppl</NO>
<PG>829-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-05-07 14:06:04 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Little-2000" NAME="Little 2000" TYPE="JOURNAL_ARTICLE">
<AU>Little DR, Mann BL, Godbout CJ</AU>
<TI>How family physicians distinguish acute sinusitis from upper respiratory tract infections: a retrospective analysis</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mucha-2003" NAME="Mucha 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mucha SM, Baroody FM</AU>
<TI>Sinusitis update</TI>
<SO>Current Opinion in Allergy and Clinical Immunology</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>1</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mygind-1976" MODIFIED="2011-06-14 22:10:18 +1000" MODIFIED_BY="[Empty name]" NAME="Mygind 1976" TYPE="JOURNAL_ARTICLE">
<AU>Mygind N, Prytz S, Sorensen H, Pedersen CB</AU>
<TI>Long term treatment of nasal polyps with beclomethasone dipropionate aerosol. Treatment and rationale</TI>
<SO>Acta Otolaryngologica (Stockholm)</SO>
<YR>1976</YR>
<VL>82</VL>
<PG>252-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mygind-2001" MODIFIED="2011-04-20 07:15:48 +1000" MODIFIED_BY="[Empty name]" NAME="Mygind 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mygind N, Nielsen LP, Hoffmann HJ, Shukla A, Blumberga G, Dahl R, et al</AU>
<TI>Mode of action of intranasal corticosteroids</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>Suppl 1</NO>
<PG>16-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piccirillo-2001" NAME="Piccirillo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Piccirillo JF, Mager D, Frisse M, Brophy RH, Goggin A</AU>
<TI>Impact of first-line vs. second-line antibiotics for the treatment of acute uncomplicated sinusitis</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>15</NO>
<PG>1849-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-08-20 10:12:46 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sahay-1980" MODIFIED="2011-06-14 22:11:09 +1000" MODIFIED_BY="[Empty name]" NAME="Sahay 1980" TYPE="JOURNAL_ARTICLE">
<AU>Sahay JN, Ibrahim NBN, Chatterjee SS, Nassar WY, Lodge KV, Jones CW</AU>
<TI>Long term study of flunisolide treatment in perennial rhinitis with special reference to nasal mucosal histology and morphology</TI>
<SO>Clinical Allergy</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scadding-2000" NAME="Scadding 2000" TYPE="JOURNAL_ARTICLE">
<AU>Scadding GK</AU>
<TI>Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>Suppl 62</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schenkel-2000" MODIFIED="2011-06-14 22:11:37 +1000" MODIFIED_BY="[Empty name]" NAME="Schenkel 2000" TYPE="JOURNAL_ARTICLE">
<AU>Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A</AU>
<TI>Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<PG>E22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seigel-1988" NAME="Seigel 1988" TYPE="JOURNAL_ARTICLE">
<AU>Seigel SC</AU>
<TI>Topical intranasal corticosteroid therapy in rhinitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>984-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaikh-2012" MODIFIED="2013-08-20 13:18:39 +1000" MODIFIED_BY="[Empty name]" NAME="Shaikh 2012" TYPE="COCHRANE_REVIEW">
<AU>Shaikh N, Wald ER, Pi M</AU>
<TI>Decongestants, antihistamines and nasal irrigation for acute sinusitis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2013-08-20 13:18:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-20 13:18:39 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007909.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shapiro-1992" NAME="Shapiro 1992" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Rachelefski GS</AU>
<TI>Introduction and definition of sinusitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1992</YR>
<VL>90</VL>
<PG>417-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shrum-2001" NAME="Shrum 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shrum KM, Grogg SE, Barton P, Shaw HH, Dyer RR</AU>
<TI>Sinusitis in children: the importance of diagnosis and treatment</TI>
<SO>Journal of the American Osteopathic Association</SO>
<YR>2001</YR>
<VL>101</VL>
<NO>Suppl 5</NO>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slavin-2005" MODIFIED="2011-06-14 22:12:22 +1000" MODIFIED_BY="[Empty name]" NAME="Slavin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, et al</AU>
<TI>The diagnosis and management of sinusitis: a practice parameter update</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>Suppl 6</NO>
<PG>13-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snow-2001" MODIFIED="2011-04-20 07:17:09 +1000" MODIFIED_BY="[Empty name]" NAME="Snow 2001" TYPE="JOURNAL_ARTICLE">
<AU>Snow V, Mottur-Pilson C, Hickner JM</AU>
<TI>Principles of appropriate antibiotic use for acute sinusitis in adults</TI>
<SO>Annals of International Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>6</NO>
<PG>495-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spector-1998" MODIFIED="2011-04-20 07:17:22 +1000" MODIFIED_BY="[Empty name]" NAME="Spector 1998" TYPE="JOURNAL_ARTICLE">
<AU>Spector SL, Bernstein IL, Li JT, Berger WE, Kaliner MA, Schuller DE, et al</AU>
<TI>Parameters for the diagnosis and management of sinusitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>Suppl</NO>
<PG>107-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2011" MODIFIED="2013-09-03 11:11:03 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2011" TYPE="COCHRANE_REVIEW">
<AU>Venekamp RP, Thompson MJ, Hayward G, Heneghan CJ, Del Mar CB, Perera R, et al</AU>
<TI>Systemic corticosteroids for acute sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-09-03 11:11:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-03 11:11:03 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008115.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wald-1988" NAME="Wald 1988" TYPE="JOURNAL_ARTICLE">
<AU>Wald ER</AU>
<TI>Sinusitis in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>Suppl 11</NO>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1993" NAME="Williams 1993" TYPE="JOURNAL_ARTICLE">
<AU>Williams JW Jr, Simel DL</AU>
<TI>Practice variation for managing acute sinusitis</TI>
<SO>Clinical Research</SO>
<YR>1993</YR>
<VL>41</VL>
<PG>566A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winstead-2003" NAME="Winstead 2003" TYPE="JOURNAL_ARTICLE">
<AU>Winstead W</AU>
<TI>Rhinosinusitis</TI>
<SO>Primary Care</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>1</NO>
<PG>137-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winther-1990" MODIFIED="2011-06-14 22:12:32 +1000" MODIFIED_BY="[Empty name]" NAME="Winther 1990" TYPE="JOURNAL_ARTICLE">
<AU>Winther B, Gwaltney JM Jr</AU>
<TI>Therapeutic approach to sinusitis: antiinfectious therapy as the baseline of management</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1990</YR>
<VL>103</VL>
<NO>5 (Pt 2)</NO>
<PG>876-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zeiger-1992" NAME="Zeiger 1992" TYPE="JOURNAL_ARTICLE">
<AU>Zeiger RS</AU>
<TI>Prospects for ancillary treatment of sinusitis in the 1990s</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1992</YR>
<VL>90</VL>
<PG>478-95</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-09-03 11:16:20 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Zalmanovici-2007" MODIFIED="2013-09-03 11:15:31 +1000" MODIFIED_BY="Liz Dooley" NAME="Zalmanovici 2007" TYPE="COCHRANE_REVIEW">
<AU>Zalmanovici A, Yaphe J</AU>
<TI>Steroids for acute sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-09-03 11:15:31 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2013-09-03 11:15:31 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD005149.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zalmanovici-2009" MODIFIED="2013-09-03 11:14:41 +1000" MODIFIED_BY="[Empty name]" NAME="Zalmanovici 2009" TYPE="COCHRANE_REVIEW">
<AU>Zalmanovici A, Yaphe J</AU>
<TI>Intranasal steroids for acute sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-09-03 11:14:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-03 11:14:41 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005149.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zalmanovici-Trestioreanu-2011" MODIFIED="2013-09-03 11:16:20 +1000" MODIFIED_BY="[Empty name]" NAME="Zalmanovici Trestioreanu 2011" TYPE="COCHRANE_REVIEW">
<AU>Zalmanovici Trestioreanu A, Yaphe J</AU>
<TI>Intranasal steroids for acute sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-09-03 11:16:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-03 11:16:20 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005149.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-02 15:33:08 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-02 15:33:08 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-27 22:09:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlan-1997">
<CHAR_METHODS MODIFIED="2013-11-27 22:09:29 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised: method of randomisation not mentioned<BR/>Allocation concealment not mentioned<BR/>Double-blind: yes<BR/>Intention-to-treat not mentioned<BR/>Follow-up described<BR/>151 recruited; 89 (59%) completed study; 41% drop-out<BR/>Design: parallel<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-27 22:09:33 +1000" MODIFIED_BY="[Empty name]">
<P>N = 89; 42 male, 47 female<BR/>Age 1 to 15 years<BR/>Inclusion criteria: 2 of 3 major criteria - purulent nasal discharge, cough, purulent pharyngeal drainage or 1 major and 2 minor criteria: facial pain, periorbital oedema, earache, tooth pain, sore throat, headache, increased wheeze, fever, foul breath for more than 7 days and Rx criteria<BR/>Water radiographs at the beginning of study positive if complete opacification or maxillary mucoperiosteal thickening more than 4 mm. 79 participants had positive Rx<BR/>Exclusion criteria: history of allergic rhinitis, asthma, recurrent/chronic sinusitis<BR/>Baseline characteristics: similar in both groups, no significant differences<BR/>Patients maintained daily symptom cards and were examined by the same physician each week. Symptom scores were evaluated by a scale from 0 to 3<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 22:09:37 +1000" MODIFIED_BY="[Empty name]">
<P>Tx group: budesonide 50 µg bid nasal spray to each nostril, N = 43<BR/>C group: placebo nasal spray bid, N = 46<BR/>All participants in both groups received amoxicillin-clavulanate potassium 40 mg/kg/day tid<BR/>Duration: 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-27 22:09:37 +1000" MODIFIED_BY="[Empty name]">
<P>Difference in weekly symptom scores for cough and nasal discharge in the first, second and third week of the study in both groups, as difference between groups or change from baseline<BR/>Relapse: results were reported as medians of scores using non-parametric tests because a wide range of scores without normal distribution</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Marmara University Hospital Outpatient Clinic patients enrolled from November 1993 to October 1994<BR/>Informed consent signed by all parents. 151 patients enrolled, 89 completed study, 62 dropped out, no separate data for both groups<BR/>Reasons for drop-outs: non-compliance with weekly visits or not recording daily symptoms</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-27 22:10:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolor-2001">
<CHAR_METHODS MODIFIED="2013-11-27 22:09:45 +1000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomisation - permuted blocks scheme stratified by site with a block size of 4 generated using SAS version 6.12<BR/>Allocation concealment - study kits administered sequentially by blinding site personnel to block size<BR/>Blinding: yes<BR/>Intention-to-treat: yes<BR/>Follow-up described: yes<BR/>88 (93%) completed study<BR/>Design: parallel<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-20 10:24:17 +1000" MODIFIED_BY="[Empty name]">
<P>N = 95; 30 men, 65 women<BR/>Age 30 to 50; median age 39 years<BR/>Inclusion criteria: older than 18 years, history of recurrent sinusitis or chronic rhinitis and clinical evidence of acute sinusitis confirmed Rx or by nasal endoscopy<BR/>Diagnosis of acute sinusitis: clinical criteria - participants with 2 of the 5 following symptoms present were enrolled: headache, facial pain, nasal congestion, thick coloured nasal discharge, olfactory disturbance<BR/>Rx criteria: air-fluid level, mucosal thickening or opacification of sinus<BR/>Exclusion criteria: previous sinus surgery, sinus lavage in the past 7 days, nasal polyposis, recurrent epistaxis, chronic bacterial sinusitis with failure of antibiotic therapy, INCS use within past 14 days, chronic use of corticosteroids or immunosuppressives, immunocompromised, allergy to penicillin/cephalosporins, participants without a telephone, pregnant, nursing women<BR/>Baseline characteristics - similar in both groups, no significant differences<BR/>Participants assessed at baseline, 10, 21, 56 days by diary records and telephone follow-up<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 22:10:06 +1000" MODIFIED_BY="[Empty name]">
<P>Tx group: nasal spray fluticasone propionate 2 puffs (total dose 200 µg) once daily in each nostril; N = 47<BR/>C group: nasal spray placebo 2 puffs once daily in each nostril; N = 48<BR/>All participants in both groups received 2 puffs xylometazoline hydrochloride in each nostril twice daily 10 minutes before the study nasal spray and 250 mg cefuroxime axetil twice daily for 10 days<BR/>Duration of study: 21 days<BR/>Follow-up: 8 weeks<BR/>Allowed to continue: NSAIDs, analgesics, immunotherapy for allergies, orally inhaled corticosteroids<BR/>Not permitted during study: oral decongestants, mucolytics, corticosteroids oral or parenteral, antihistamines, immunosuppressives<BR/>Sinus lavage or sinus surgery was discouraged during the first 3 weeks of the trial, antibiotic use in the past 7 days or 21 days if longer half-life was not permitted<BR/>Compliance with Tx: assessed by a standardised form given to patients for recording daily symptoms, Tx, adverse events, work attendance. 94% completed study Tx without difference between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-20 10:24:26 +1000" MODIFIED_BY="[Empty name]">
<P>Proportion of patients with clinical success (cured or much improved) at 10, 21, 56 days on telephone follow-up<BR/>Time to clinical success differences over time in sinusitis and quality of life scores<BR/>Level of work performance<BR/>Total number of hours lost from work<BR/>Recurrences</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Study conducted between October 1998 to April 2000 at 22 sites (12 primary care and 10 otolaryngology)<BR/>Equal proportions of participants from primary care and otolaryngology practices in both treatment arms<BR/>All study sites received standardised instructions for conducting the study<BR/>Study progress monitored by a research associate<BR/>Patients assessed symptoms on numeric scales and received booklets with specific instructions for use of nasal spray<BR/>High agreement between patient-recorded and interviewer-obtained symptoms<BR/>Drop-outs:<BR/>Tx group: 1 - rash, 1 - unknown, 1 - lost to follow-up<BR/>44 completed 21-day Tx and telephone follow-up, 36 completed diary, 46 included in primary analysis<BR/>C group: 1 - withdrew, 2 - switched to different antibiotics<BR/>45 completed 21-day Tx, 44 completed telephone follow-up, 32 completed diary, 46 included in primary analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-27 22:10:33 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Meltzer-2005">
<CHAR_METHODS MODIFIED="2013-11-27 22:10:15 +1000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomisation<BR/>1:1:1:1 ratio to 1 of 4 arms by computer-generated code<BR/>Allocation concealment: not mentioned<BR/>Double-blind: yes<BR/>Intention-to-treat: yes<BR/>Follow-up described<BR/>10% drop-out in Tx phase, 95% completed follow-up phase<BR/>Design: parallel<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="Liz Dooley">
<P>N = 981; 338 men, 643 women<BR/>Age 12 to 76 years<BR/>Inclusion criteria: age more than 12 years with clinical criteria for acute sinusitis; MSS more than 5 but less than 12 at baseline, assessed by participant and investigator and no more than 3/5 symptoms rated severe (rhinorrhoea, PND nasal congestion, stuffiness, sinus headache and facial pain on pressure) adding cough to the TSS<BR/>Exclusion criteria: fulminant bacterial rhinosinusitis, chronic rhinosinusitis, nasal/sinus surgery within the last 6 months for this condition, otitis, atrophic rhinitis, nasal polyps, symptomatic seasonal allergic rhinitis, allergy to corticosteroids<BR/>Asthmatic participants needed to be stable last 30 days and FEV1 more than 65% last 3 months before screening<BR/>Rhinoscopic examination was performed at all visits<BR/>Participants were assessed at baseline days 8, 15, 29 and monitored by telephone on days 3 to 4. Response to Tx evaluated by participant and investigator as scores for symptoms on a scale from 0 to 3<BR/>Baseline characteristics similar for all the arms<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 22:10:33 +1000" MODIFIED_BY="[Empty name]">
<P>4 groups<BR/>Tx groups:<BR/>1. MFNS 200 µg once daily nasal spray + placebo nasal spray once daily + placebo capsules tid; N = 243<BR/>2. MFNS 200 µg nasal spray bid + placebo capsules tid; N = 235<BR/>3. amoxicillin 500 mg tid for 10 days + placebo nasal spray bid; N = 251<BR/>C group: placebo nasal spray bid + placebo capsules tid; N = 252<BR/>Duration of study: 15 days<BR/>Capsules given for 10 days<BR/>Follow-up: 14 days<BR/>Not allowed during study: nasal saline, nasal cromolyn sodium, ipratropium bromide, corticosteroids (excluding oral inhaled corticosteroids for mild/moderate asthma), antihistamines, decongestants, leukotriene pathway modificants, analgesics, NSAID<BR/>Compliance assessed at days 8 and 15 by questioning whether drug had been taken<BR/>Each participant received at least 1 dose of study drug</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean MSS<BR/>Mean TSS<BR/>Individual scores<BR/>Time to onset of action<BR/>Global response to Tx<BR/>Adverse events<BR/>Disease recurrence<BR/>Tx failure (worsening or not improvement in symptoms during the Tx phase)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Study conducted at 71 medical centres in 14 countries from January to September 2003<BR/>Drop-outs: during the Tx phase in the 200 µg, 400 µg MFNS, amoxicillin, placebo were 9%, 9%, 8%, 13%<BR/>Reasons for discontinuation: adverse events, Tx failure, loss to follow-up, did not wish to continue, non-compliance with protocol, did not meet protocol criteria for entry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-27 22:10:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nayak-2002">
<CHAR_METHODS MODIFIED="2013-11-27 22:10:35 +1000" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised; method of randomisation not mentioned<BR/>Allocation concealment not mentioned<BR/>Double-blind: yes<BR/>Follow-up described: yes<BR/>864 (89%) participants included in the primary efficacy analysis<BR/>Design: parallel<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="Liz Dooley">
<P>N = 967; 402 men, 565 women<BR/>Age 8 to 78 years<BR/>Inclusion criteria: acute episode of rhinosinusitis, at least 1 moderate/severe nasal symptom (these may include purulent rhinorrhoea, stuffiness/congestion, post-nasal drip, sinus headache, facial pain, cough), purulent rhinorrhoea present, sinusitis confirmed by a CT scan, which is read by a radiologist at each study site at baseline, a total symptom score more than 6<BR/>Exclusion criteria: nasal polyps, cystic fibrosis, Kartagener syndrome, expected immediate sinus or nasal surgery, glaucoma, history of subcapsular cataracts, clinical significant diseases<BR/>Symptoms evaluated at baseline (day 1) and day 21 by patient and investigator by scales. Patients evaluated at baseline, 15, 21 days<BR/>CT scans of paranasal sinuses at baseline and 21 days evaluated by an independent blinded radiologist<BR/>Similar baseline characteristics and baseline symptoms scores in all 3 groups<BR/>Patients recorded symptom scores, adverse events and use of medication twice daily<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>3 groups<BR/>Tx groups:<BR/>1 MFNS 400 µg nasal spray twice daily; N = 324<BR/>2 MFNS 200 µg nasal spray twice daily; N = 318<BR/>C group:<BR/>Matching placebo nasal spray twice daily; N = 325<BR/>All participants in all groups received amoxicillin-clavulanate potassium 875 mg twice daily for 21 days<BR/>Not allowed during study: any form of corticosteroid, nasal decongestants, antihistamines<BR/>Washout period before the baseline visit for previous use of antibiotics, intranasal or systemic corticosteroids, decongestants<BR/>Adherence to therapy assessed by weighing the nasal spray dosing containers without patients' knowledge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<P>Improvement in total symptoms score<BR/>Improvement in individual symptom score<BR/>Overall response to treatment: proportion of participants with complete or marked relief<BR/>Onset of relief<BR/>Evaluation of changes in CT scans of sinuses<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients from 61 Tx centres in the US<BR/>967 participants randomised, 103 participants (11%) not included in analysis because CT did not confirm sinusitis and excluded post-randomisation, diary data not available, less than 80% compliance with Tx, less than 7 days Tx (32, 36, 35 in the MFNS 400, 200 µg and placebo groups)<BR/>Reasons for exclusion or discontinuation were evenly distributed among the groups<BR/>Physician evaluation of symptoms at day 21 was consistent with patient-recorded evaluation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>bid: twice daily<BR/>C: control<BR/>CT: computed tomography<BR/>FEV1: forced expiratory volume in one second<BR/>INCS: intranasal corticosteroid<BR/>ITT: intention-to-treat<BR/>MFNS: mometasone furoate<BR/>MSS: major symptom score<BR/>NSAID: non-steroidal anti-inflammatory drugs<BR/>PND: post-nasal drip<BR/>Rx: radiological<BR/>tid: three times daily<BR/>TSS: total symptom score<BR/>Tx: treatment<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-08-20 10:25:37 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-03-02 08:45:57 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Bachert-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-02 08:45:57 +1000" MODIFIED_BY="Liz Dooley">
<P>Study on quality of life. Outcome for a subset of patients from one of the included studies (<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gehanno-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel<BR/>Participants: N = 433 adults with confirmed acute sinusitis<BR/>Intervention: amoxicillin-clavulanate and methylprednisolone or placebo per oral administration<BR/>No intranasal steroids used<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-28 04:11:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jurkiewicz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-28 04:11:09 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract and full paper not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel<BR/>Participants: N = 175 participants 14 years or older with confirmed acute or chronic sinusitis<BR/>Intervention: amoxicillin-clavulanate potassium combined with nasal spray of either flunisolide or placebo<BR/>No separate arms for acute and chronic sinusitis reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-20 10:25:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-20 10:25:37 +1000" MODIFIED_BY="[Empty name]">
<P>Missing data - number randomised, numbers included in analyses, drop-outs and reasons for drop-out. The numbers reported do not add up to 100%. An email was sent to the author but there was no reply</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quarnberg-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel<BR/>Participants: N = 40 participants 16 years or older with confirmed recurrent or chronic sinusitis<BR/>Intervention: erythromycin and either budesonide or placebo aerosol<BR/>Separate arms for acute recurrent and chronic sinusitis were not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-02 08:48:07 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Tutkun-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-02 08:48:07 +1000" MODIFIED_BY="Liz Dooley">
<P>Missing data - not mentioned acute/chronic sinusitis, diagnostic criteria not reported, drop-outs not reported. Email was sent to the author but there was no reply</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-14 22:06:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Williamson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-14 22:06:42 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria for the review were not met</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yilmaz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 10:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel<BR/>Participants: 52 children with confirmed acute sinusitis<BR/>Intervention: cefaclor and either oral pseudoephedrine or intranasal budesonide<BR/>No placebo used in the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-12-28 03:33:46 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-02 15:33:08 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-05-07 14:12:06 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>Randomised, method not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:12:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-07 14:12:09 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:12:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-20 09:18:46 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-14 22:01:51 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-07 14:11:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>No separate data for groups, ITT not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 22:01:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-07 14:12:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-07 14:12:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>See notes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-12-02 15:33:05 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-07 14:11:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>No evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 22:01:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:32:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:33:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-12-02 15:33:08 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:32:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:32:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:33:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:33:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-05-07 14:12:13 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-07 14:11:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-07 14:11:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-07 14:11:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-07 14:12:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>See methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-12-02 15:33:07 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-02 15:32:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlan-1997">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-02 15:32:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolor-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-02 15:33:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2005">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-02 15:33:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-11-27 21:48:38 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Adverse events</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Side effects</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dolor-2001" TYPE="STUDY">Dolor 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluticasone propionate 2 puffs - total dose 200 µg or placebo nasal spray once daily in addition to 250 mg cefuroxime axetil orally twice daily and 2 puffs of xylometazoline hydrochloride twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache, bloody nose, vaginal itching, yeast infection, nausea, stomach irritation, diarrhoea, increased congestion, hay fever, light-headed, sore throat, thirsty, itching, rash, cough, fatigue, metallic taste, felt dried out, nasal tissue felt inflamed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No serious unexpected adverse events reported<BR/>
<BR/>Any adverse event - 37% in the fluticasone group versus 20% in the placebo group (P value = 0.7) no statistical significant difference<BR/>
<BR/>Adverse events could be attributed also to the co-treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amoxicillin-clavulanate potassium 875 mg<BR/>twice daily orally and MFNS 200, 400 µg or placebo nasal spray twice daily</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Epistaxis was the most frequently reported adverse event<BR/>Nasal burning, irritation and headache occurred in less than 2% of any treatment group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment well-tolerated, adverse events similar for all 3 arms of mild/moderate intensity: 12%, 15%, 15% in the MFNS 400, 800 µg and placebo arms<BR/>
<BR/>50 patients discontinued treatment because of adverse events, most commonly diarrhoea and nausea due to the antibiotic and were equally distributed among groups. Epistaxis, nasal burning, irritation or infection were not a cause for discontinuation of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Barlan-1997" TYPE="STUDY">Barlan 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Budesonide 50 µg or placebo nasal spray to each nostril bid in addition to amoxicillin clavulanate potassium 40 mg/kg/day tid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rash after 1 week attributed to the antibiotic in 1 subject that was switched to cefaclor</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No specific adverse events related to the INCS use were reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Meltzer-2005" TYPE="STUDY">Meltzer 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MFNS 200 µg once daily or twice daily nasal spray<BR/>Amoxicillin 500 mg tid<BR/>Placebo nasal spray and capsules</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache and epistaxis were most common reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most adverse events were mild or moderate with a similar incidence among treatment groups: 36.2%,<BR/>35.4%, 33.5% and 38.1% with MFNS 200 µg, 400 µg,<BR/>amoxicillin and placebo<BR/>1%, 3%, 2% and 2% of participants discontinued treatment because of adverse events in the 200 µg, 400 µg INCS, antibiotic and placebo arms</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>bid: twice daily<BR/>INCS: intranasal corticosteroid<BR/>MFNS: mometasone furoate<BR/>tid: three times daily</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-11-27 21:44:57 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-27 21:44:57 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intranasal corticosteroids versus placebo</NAME>
<DICH_OUTCOME CHI2="1.2962024714534999" CI_END="1.175971668438991" CI_START="1.0230282628507117" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0968373868193926" ESTIMABLE="YES" EVENTS_1="402" EVENTS_2="385" I2="22.851558917439224" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="0.07039685882445139" LOG_CI_START="0.009887631982497461" LOG_EFFECT_SIZE="0.0401422454034744" METHOD="MH" MODIFIED="2013-11-27 21:43:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25490817058129" P_Q="0.0" P_Z="0.00930859292108459" Q="1.5244812038480686E-31" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="553" TOTAL_2="577" WEIGHT="99.99999999999999" Z="2.6005077028955723">
<NAME>Proportion of participants with resolution of symptoms or improved (MFNS 400 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 400 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MFNS 400 µg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1237735568845446" CI_START="1.0141858543698508" EFFECT_SIZE="1.0675744680851065" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="225" LOG_CI_END="0.05067880865028546" LOG_CI_START="0.006117548814930887" LOG_EFFECT_SIZE="0.028398178732608186" ORDER="18318" O_E="0.0" SE="0.026175504609080975" STUDY_ID="STD-Meltzer-2005" TOTAL_1="235" TOTAL_2="252" VAR="6.851570415400193E-4" WEIGHT="57.843234581581264"/>
<DICH_DATA CI_END="1.317400127842504" CI_START="0.9812842313415958" EFFECT_SIZE="1.1369889937106918" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="160" LOG_CI_END="0.11971770125009139" LOG_CI_START="-0.008205179955269577" LOG_EFFECT_SIZE="0.055756260647410905" ORDER="18319" O_E="0.0" SE="0.0751425336485036" STUDY_ID="STD-Nayak-2002" TOTAL_1="318" TOTAL_2="325" VAR="0.005646400363116495" WEIGHT="42.15676541841872"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9245523884279505" CI_END="1.1100900158883276" CI_START="0.9800047866575384" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0430213464696223" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="255" I2="79.69358591148571" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.04535819664118219" LOG_CI_START="-0.008771803068853222" LOG_EFFECT_SIZE="0.01829319678616448" METHOD="MH" MODIFIED="2013-11-27 21:43:21 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02647780315375603" P_Q="1.0" P_Z="0.18525839484267195" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="300" WEIGHT="100.0" Z="1.3247370055440482">
<NAME>Proportion of participants with resolution of symptoms or improved (MFNS 200 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 200 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MFNS 200 µg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7124835948951072" CI_START="1.0293120184808218" EFFECT_SIZE="1.327659574468085" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="30" LOG_CI_END="0.23362641976699985" LOG_CI_START="0.012547043726413139" LOG_EFFECT_SIZE="0.1230867317467065" ORDER="18320" O_E="0.0" SE="0.1298631198468017" STUDY_ID="STD-Dolor-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.016864429896344787" WEIGHT="11.84557223049605"/>
<DICH_DATA CI_END="1.067279248016347" CI_START="0.9459287387377107" EFFECT_SIZE="1.0047736625514403" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="225" LOG_CI_END="0.028278065165425987" LOG_CI_START="-0.024141579812477554" LOG_EFFECT_SIZE="0.0020682426764742404" ORDER="18321" O_E="0.0" SE="0.03079155894144806" STUDY_ID="STD-Meltzer-2005" TOTAL_1="243" TOTAL_2="252" VAR="9.481201020446698E-4" WEIGHT="88.15442776950395"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.548098035916341" CI_END="1.1757801750648817" CI_START="1.0412692400832084" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1064825933536917" ESTIMABLE="YES" EVENTS_1="852" EVENTS_2="415" I2="79.05341993267398" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07032613323653686" LOG_CI_START="0.01756303917812896" LOG_EFFECT_SIZE="0.04394458620733289" METHOD="MH" MODIFIED="2013-11-27 21:43:46 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.008446150371976158" P_Q="1.0" P_Z="0.0010955119217157616" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1167" TOTAL_2="625" WEIGHT="99.99999999999999" Z="3.264774661870427">
<NAME>Proportion of participants with resolution of symptoms or improved (combined MFNS 200, 400 and 800 µg daily)</NAME>
<GROUP_LABEL_1>MFNS combined 200,400,800</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MFNS 200,400,800</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7124835948951072" CI_START="1.0293120184808218" EFFECT_SIZE="1.327659574468085" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="30" LOG_CI_END="0.23362641976699985" LOG_CI_START="0.012547043726413139" LOG_EFFECT_SIZE="0.1230867317467065" ORDER="18322" O_E="0.0" SE="0.1298631198468017" STUDY_ID="STD-Dolor-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.016864429896344787" WEIGHT="5.529921465253671"/>
<DICH_DATA CI_END="1.0885709915782549" CI_START="0.9852989814312181" EFFECT_SIZE="1.0356485355648535" ESTIMABLE="YES" EVENTS_1="442" EVENTS_2="225" LOG_CI_END="0.03685675698330503" LOG_CI_START="-0.006431966168995837" LOG_EFFECT_SIZE="0.015212395407154591" ORDER="18323" O_E="0.0" SE="0.02542801026229701" STUDY_ID="STD-Meltzer-2005" TOTAL_1="478" TOTAL_2="252" VAR="6.465837058994822E-4" WEIGHT="54.892247246539455"/>
<DICH_DATA CI_END="1.335026029998605" CI_START="1.0320833839931693" EFFECT_SIZE="1.1738220404984423" ESTIMABLE="YES" EVENTS_1="371" EVENTS_2="160" LOG_CI_END="0.12548973354669848" LOG_CI_START="0.013714786191585853" LOG_EFFECT_SIZE="0.06960225986914217" ORDER="18324" O_E="0.0" SE="0.065657157371306" STUDY_ID="STD-Nayak-2002" TOTAL_1="642" TOTAL_2="325" VAR="0.004310862314080442" WEIGHT="39.577831288206866"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8929853082157924" CI_END="1.2003813662398741" CI_START="0.6145954979316853" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8589231534264937" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="68" I2="47.17338821068102" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0793192451650022" LOG_CI_START="-0.2114106253855102" LOG_EFFECT_SIZE="-0.06604569011025402" METHOD="MH" MODIFIED="2013-11-27 21:44:03 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.16886581546809698" P_Q="1.0" P_Z="0.37319858917990834" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="553" TOTAL_2="577" WEIGHT="99.99999999999999" Z="0.8904979299517869">
<NAME>Number of participants that dropped out from the study (MFNS 400 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 400 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MFNS 400 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0999579166809008" CI_START="0.38399131240328355" EFFECT_SIZE="0.6499032882011605" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="33" LOG_CI_END="0.041376069791968624" LOG_CI_START="-0.41567860120016553" LOG_EFFECT_SIZE="-0.18715126570409849" ORDER="18325" O_E="0.0" SE="0.26847617619788944" STUDY_ID="STD-Meltzer-2005" TOTAL_1="235" TOTAL_2="252" VAR="0.07207945718584016" WEIGHT="47.9155646201633"/>
<DICH_DATA CI_END="1.6303014552610973" CI_START="0.6778185945083076" EFFECT_SIZE="1.0512129380053907" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.212267916214755" LOG_CI_START="-0.1688865213918484" LOG_EFFECT_SIZE="0.021690697411453286" ORDER="18326" O_E="0.0" SE="0.223892003395014" STUDY_ID="STD-Nayak-2002" TOTAL_1="318" TOTAL_2="325" VAR="0.050127629184232955" WEIGHT="52.084435379836684"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1731589800599202" CI_END="1.2052478687989387" CI_START="0.46401901741604584" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7478354978354979" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.08107637220675248" LOG_CI_START="-0.33346421989856906" LOG_EFFECT_SIZE="-0.12619392384590827" METHOD="MH" MODIFIED="2013-11-27 21:44:20 +1000" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.6773197418789219" P_Q="1.0" P_Z="0.23275211000741614" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="300" WEIGHT="100.0" Z="1.193299524901197">
<NAME>Number of participants that dropped out from the study (MFNS 200 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 200 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MFNS 200 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.806606995309268" CI_START="0.21699420943582567" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6818386141723252" LOG_CI_START="-0.6635518552925856" LOG_EFFECT_SIZE="0.009143379439869719" ORDER="18327" O_E="0.0" SE="0.7902890215539201" STUDY_ID="STD-Dolor-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.6245567375886524" WEIGHT="8.392857142857142"/>
<DICH_DATA CI_END="1.1944957354784695" CI_START="0.43735261043493945" EFFECT_SIZE="0.7227833894500562" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="33" LOG_CI_END="0.07718460359491747" LOG_CI_START="-0.3591682769490428" LOG_EFFECT_SIZE="-0.14099183667706267" ORDER="18328" O_E="0.0" SE="0.2563158420131167" STUDY_ID="STD-Meltzer-2005" TOTAL_1="243" TOTAL_2="252" VAR="0.065697810866893" WEIGHT="91.60714285714286"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5572029212975602" CI_END="1.1202730581752365" CI_START="0.6395048226592194" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8464159872062058" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.04932389160334427" LOG_CI_START="-0.1941561760541472" LOG_EFFECT_SIZE="-0.07241614222540146" METHOD="MH" MODIFIED="2013-11-27 21:44:40 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.45904770282639407" P_Q="1.0" P_Z="0.2436671052008822" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1167" TOTAL_2="625" WEIGHT="100.0" Z="1.16586981453264">
<NAME>Number of participants that dropped out from the study (combined MFNS 200, 400 and 800 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 200,400,800 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MFNS 200,400,800</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.806606995309268" CI_START="0.21699420943582567" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6818386141723252" LOG_CI_START="-0.6635518552925856" LOG_EFFECT_SIZE="0.009143379439869719" ORDER="18329" O_E="0.0" SE="0.7902890215539201" STUDY_ID="STD-Dolor-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.6245567375886524" WEIGHT="3.203614777802506"/>
<DICH_DATA CI_END="1.0530267029862017" CI_START="0.4481412646921418" EFFECT_SIZE="0.6869532141498669" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" LOG_CI_END="0.022439384302786428" LOG_CI_START="-0.3485850645605379" LOG_EFFECT_SIZE="-0.16307284012887574" ORDER="18330" O_E="0.0" SE="0.21794159786295889" STUDY_ID="STD-Meltzer-2005" TOTAL_1="478" TOTAL_2="252" VAR="0.04749854007905969" WEIGHT="46.64056011833662"/>
<DICH_DATA CI_END="1.4458271090121853" CI_START="0.66905533656109" EFFECT_SIZE="0.9835336003560302" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="35" LOG_CI_END="0.16011636343490102" LOG_CI_START="-0.1745379609029375" LOG_EFFECT_SIZE="-0.0072107987340182325" ORDER="18331" O_E="0.0" SE="0.19657760668166854" STUDY_ID="STD-Nayak-2002" TOTAL_1="642" TOTAL_2="325" VAR="0.03864275544869278" WEIGHT="50.15582510386088"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5452384043266871" CI_END="1.1508017629630483" CI_START="0.4410259255227953" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7124137931034483" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.06100051853331901" LOG_CI_START="-0.3555358799640276" LOG_EFFECT_SIZE="-0.1472676807153543" METHOD="MH" MODIFIED="2013-11-27 21:44:57 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.46026992368115016" P_Q="1.0" P_Z="0.16577677664967155" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="525" TOTAL_2="300" WEIGHT="100.00000000000001" Z="1.3859021748404392">
<NAME>Relapse (combined 200 and 400 µg daily)</NAME>
<GROUP_LABEL_1>MFNS 200,400 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MFNS 200, 400 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2562834440387518" CI_START="0.2407179619894039" EFFECT_SIZE="0.5499181669394435" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.09908763645065252" LOG_CI_START="-0.6184915021560728" LOG_EFFECT_SIZE="-0.2597019328527102" ORDER="18332" O_E="0.0" SE="0.42150953809161373" STUDY_ID="STD-Dolor-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.17767029070220558" WEIGHT="36.619868637110024"/>
<DICH_DATA CI_END="1.457435006979461" CI_START="0.44607198075636584" EFFECT_SIZE="0.8063007629830174" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.16358919688591816" LOG_CI_START="-0.3505950553619797" LOG_EFFECT_SIZE="-0.09350292923803076" ORDER="18333" O_E="0.0" SE="0.30203437502351316" STUDY_ID="STD-Meltzer-2005" TOTAL_1="478" TOTAL_2="252" VAR="0.09122476369584417" WEIGHT="63.38013136288999"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-02 15:33:09 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-02 15:33:09 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-02 15:33:09 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAAHNCAIAAAAWlbBjAAAT9ElEQVR42u3dv44cxxHH8QMMGAoY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-11-27 21:46:30 +1000" MODIFIED_BY="Liz Dooley">
<APPENDIX ID="APP-01" MODIFIED="2013-11-27 21:46:30 +1000" MODIFIED_BY="Liz Dooley" NO="1">
<TITLE MODIFIED="2010-12-17 10:21:07 +1000" MODIFIED_BY="[Empty name]">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-27 21:46:30 +1000" MODIFIED_BY="Liz Dooley">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 2, part of <I>The Cochrane Library</I>,<I> </I>www.thecochranelibrary.com (accessed 25 May 2011), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (September 2008 to May week 2, 2011) and Embase.com (October 2008 to May 2011). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of previous searches.</P>
<P>Previously we searched the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library </I>2008, Issue 4) which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (January 1966 to October 2008), EMBASE (1990 to October 2008) and bibliographies of included studies.</P>
<P>MEDLINE was searched using the following keywords and MeSH terms in conjunction with the highly sensitive search strategy designed by The Cochrane Collaboration for identifying randomised controlled trials (Lefebvre 2008). The same strategy was used to search CENTRAL and adapted to search EMBASE.</P>
<P>
<B>MEDLINE (OVID)</B>
<BR/>1 exp SINUSITIS/<BR/>2 sinusit*.tw.<BR/>3 rhinosinusit*.tw.<BR/>4 or/1-3<BR/>5 exp STEROIDS/<BR/>6 steroid*.tw.<BR/>7 exp Adrenal Cortex Hormones/<BR/>8 adrenal cortex hormone*.tw.<BR/>9 exp Anti-Inflammatory Agents/<BR/>10 anti-inflammat*.tw.<BR/>11 corticosteroid*.tw.<BR/>12 or/5-11<BR/>13 exp Administration, Intranasal/<BR/>14 exp Administration, Topical/<BR/>15 (nasal* or intranasal* or topical*).tw.<BR/>16 or/13-15<BR/>17 12 and 16<BR/>18 4 and 17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-22 14:41:23 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-12-17 10:21:19 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-22 14:41:23 +1000" MODIFIED_BY="[Empty name]">
<P>#24 #16 AND #23 <BR/>#23 #22 NOT #21 <BR/>#22 #17 OR #18 <BR/>#21 #19 NOT #20 <BR/>#20 'human'/de <BR/>#19 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de <BR/>#18 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR allocat*:ab,ti OR trial:ti OR ((doubl* OR singl*) NEAR/1 blind*):ab,ti <BR/>#17 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#16 #4 AND #11 AND #15 <BR/>#15 #12 OR #13 OR #14 <BR/>#14 nasal*:ab,ti OR intranasal*:ab,ti OR topical*:ab,ti <BR/>#13 'topical drug administration'/de <BR/>#12 'intranasal drug administration'/de <BR/>#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10 <BR/>#10 'adrenal cortex hormone':ab,ti OR 'adrenal cortex hormones':ab,ti <BR/>#9 'anti-inflammatory':ab,ti OR 'anti-inflammatories':ab,ti OR antiinflammat*:ab,ti OR 'anti inflammatory':ab,ti OR 'anti inflammatories':ab,ti <BR/>#8 'antiinflammatory agent'/exp <BR/>#7 'corticosteroid'/exp <BR/>#6 steroid*:ab,ti <BR/>#5 'steroid'/exp <BR/>#4 #1 OR #2 OR #3 <BR/>#3 rhinosinusit*:ab,ti OR nasosinusit*:ab,ti <BR/>#2 sinusit*:ab,ti <BR/>#1 'sinusitis'/exp </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>